T. cruzi, the causative agent of Chagas disease, relies on its enzyme trans-sialidase for part of its infectivity. Robert Field et al., from several collaborating institutions worldwide, have studied this enzyme, highlighting the wide range of structures and functionalities that it can accommodate. This study has demonstrated important features for potential inhibitor design (a therapeutic target for Chagas’ disease) and also opens up possibilities for using the versatility of this enzyme more generally as a catalyst for α-(2→3)-sialylglycoconjugate synthesis.
This HOT article is now free to access until 22nd February.
Probing the acceptor substrate binding site of Trypanosoma cruzi trans-sialidase with systematically modified substrates and glycoside libraries
Jennifer A. Harrison, K. P. Ravindranathan Kartha, Eric J. L. Fournier, Todd L. Lowary, Carles Malet, Ulf J. Nilsson, Ole Hindsgaul, Sergio Schenkman, James H. Naismith and Robert A. Field
Org. Biomol. Chem., 2011, Advance Article
DOI: 10.1039/C0OB00826E, Paper
